Author

Yu-Chung Huang

Boston Children's HospitalORCID 0000-0003-4513-518XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Adam von Paternos· 1 shared Allison Tompkins· 1 shared Annie LiiD· 1 shared Anthony John IafrateiD· 1 shared Anup VaidyaiD· 1 shared Arianna MarkeliD· 1 shared Atul K. Bhan· 1 shared Benoît LaurentiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam von Paternos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal for ImmunoTherapy of CancerPeer-reviewedApr 1, 2025

Reversible Downregulation of HLA Class I in Adenoid Cystic Carcinoma

Annie Li, Bianca L Gonda, Elizabeth M. Codd…·Anthony John Iafrate

This study identifies low HLA/B2M class I expression in ACC tumors and shows it can be reversed by interferon-ψ or STING agonists, suggesting a path for immunotherapy.

12 citationstop 4%

humanspatial transcriptomics

𝕏 PostBluesky

GenomicsbioRxivPreprintJan 31, 2025

Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers

Mohamad Ali Toufic Najia, Deepak Kumar Jha, Cheng Zhang…·George Q. Daley

The paper identifies KDM4 demethylase inhibition as a therapeutic strategy for lymphoma and other cancers by rewiring heterochromatin and inducing DNA damage.

1 citation

humanChIP-seq

𝕏 PostBluesky